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The epidermal growth factor receptor (EGFR) is upre-
gulated in numerous human cancers. Inhibition of
EGFR signaling induces autophagy in tumor cells.
Here, we report an unanticipated role for the inactive
EGFR in autophagy initiation. Inactive EGFR inter-
acts with the oncoprotein LAPTM4B that is required
for the endosomal accumulation of EGFR upon
serum starvation. Inactive EGFR and LAPTM4B sta-
bilize each other at endosomes and recruit the exo-
cyst subcomplex containing Sec5. We show that
inactive EGFR, LAPTM4B, and the Sec5 subcomplex
are required for basal and starvation-induced auto-
phagy. LAPTM4B and Sec5 promote EGFR associa-
tion with the autophagy inhibitor Rubicon, which in
turn disassociates Beclin 1 from Rubicon to initiate
autophagy. Thus, the oncoprotein LAPTM4B facili-
tates the role of inactive EGFR in autophagy initia-
tion. This pathway is positioned to control tumor
metabolism and promote tumor cell survival upon
serum deprivation or metabolic stress.
INTRODUCTION
Autophagy (macroautophagy) is a self-eating process by which
part of the cytoplasm, organelles, and/or membrane are en-
gulfed and eventually digested in lysosomes for cell homeosta-
sis, development, and/or nutrient recycling (Feng et al., 2014).
Autophagy is inducible by nutrient starvation as a mechanism
to protect cells (Klionsky et al., 2012). The core machinery
required for autophagosome formation consists of autophagy-
related (Atg) proteins that function in a specific order (Feng
et al., 2014). The Beclin 1 (Atg6 in yeast) complex containing
Beclin 1, VPS34, ATG14, and VPS15 plays essential roles in
phagophore nucleation and autophagy initiation and is emerging
as a regulatory complex by autophagy signals (He and Levine,
2010; Matsunaga et al., 2009; Sun et al., 2009; Zhong et al.,
2009). LC3 (Atg8 in yeast) is an autophagy regulator downstream
of Beclin 1, and a hallmark of autophagosome formation is the
conversion of the cytosolic LC3-I into the lipidated LC3-II that as-
sociates with autophagosomemembranes (Kabeya et al., 2000).
The exocyst also plays a role in the Beclin 1 complex assembly
during autophagy initiation (Bodemann et al., 2011), but howand where the exocyst and the autophagy complexes are regu-
lated is not defined.
Epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase that plays fundamental roles in physiology and
cancers (Schlessinger, 2000). Aberrant EGFR signaling due to
EGFR mutations and/or protein overexpression is associated
with most epithelial cancers (Mendelsohn and Baselga, 2006).
Recent studies have shown a role for EGFR signaling in
autophagy suppression by activation of the PI3K/AKT/mTOR
pathway or by EGFR-mediated phosphorylation and inhibition
of Beclin 1 (Wei et al., 2013). Autophagy is generally thought
to prevent cancer initiation but is also positioned to promote
cancer cell survival upon metabolic stress (Brech et al., 2009;
White, 2012). Rapamycin, an autophagy inducer, exhibits cyto-
toxic effects in cancer cells treated with EGFR tyrosine kinase
inhibitors (TKIs) erlotinib or gefitinib (Fung et al., 2012; Gorzalc-
zany et al., 2011). However, autophagy induced by EGFR TKIs or
neutralizing antibody shows cytoprotective roles (Choi et al.,
2013; Dragowska et al., 2013; Eimer et al., 2011; Han
et al., 2011; Li and Fan, 2010; Li et al., 2010b; Sobhakumari
et al., 2013; Zou et al., 2013), suggesting that EGFR TKIs (or
neutralizing antibody) may induce autophagy by a mechanism
distinct from rapamycin. At least some EGFR-overexpressing
cells and tumors are dependent on autophagy for growth and
survival (Jutten et al., 2013; Jutten and Rouschop, 2014). A
gefitinib-resistant subpopulation of lung adenocarcinoma cells
depend on enhanced autophagic activity, but not on EGFR
signaling, for survival (Sakuma et al., 2013). The combined
data suggest a kinase-independent role for EGFR in autophagy
that regulates cancer cell survival.
The lysosomal-associated transmembrane protein 4B
(LAPTM4B) is a tetratransmembrane protein localized primarily
to the late endosome and lysosome (Liu et al., 2004). LAPTM4B
was originally identified in hepatocellular carcinoma patients
as an abnormally overexpressed protein and was later found to
be upregulated in many other human cancers, including breast,
lung, ovarian, and colon cancers (Kasper et al., 2005). Ectopic
expression of LAPTM4B transforms normal cells and promotes
proliferation, migration, and invasion of cancer cells (Li et al.,
2011a; Yang et al., 2010). LAPTM4B is proposed to promote
cancer cell proliferation by upregulating PI3K/ATK signaling (Li
et al., 2010a). We have shown that LAPTM4B blocks EGF-stim-
ulated EGFR intraluminal sorting and lysosomal degradation,
resulting in enhanced and prolonged EGFR signaling (X.T.,
Y.S., N.T., Y. Liao, A.C. Hedman, and R.A.A., unpublished
data). A potential role for LAPTM4B in the promotion or inhibitionCell 160, 145–160, January 15, 2015 ª2015 Elsevier Inc. 145
Figure 1. EGFR, but Not Its Kinase Activity, Is Required for Autophagy
(A) Knockdown of EGFR inhibits basal and serum starvation-induced LC3-II (autophagosome marker) turnover in MDA-MB-231 cells. Cells transfected with
indicated siRNAs were cultured in normal medium (N) or serum-free starvation medium (S) for 24 hr and then were treated with 80 mM chloroquine (CQ) for 2 hr to
induce LC3-II accumulation. Whole-cell lysates were harvested for western blot analysis of LC3-II.
(legend continued on next page)
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of autophagosome maturation has been proposed (Li et al.,
2011b; Vergarajauregui et al., 2011).
Here, we report an unexpected role for inactive EGFR in auto-
phagy initiation. Upon serum starvation, inactive EGFR collabo-
rates with LAPTM4B and Sec5 at endosomes to disassociate
Rubicon from Beclin 1, which in turn initiates autophagy. EGFR
TKIs also induce autophagy initiation, revealing that kinase-inac-
tive EGFR functions in autophagy, and this may be a mechanism
for tumor cell resistance to EGFR TKIs.
RESULTS
EGFR, but Not Its Kinase Activity, Is Required for
Autophagy
EGFR TKIs induce autophagy (Han et al., 2011; Jutten and Rou-
schop, 2014; Li et al., 2010b), suggesting a direct role for inactive
EGFR in autophagy upregulation. To test this hypothesis, we
examined if EGFR is required for autophagic flux. Knockdown
of EGFR inhibited basal and serum starvation-induced autopha-
gic flux (Figure 1A), as shown by the LC3-II levels, before and af-
ter inhibition of its degradation by chloroquine. Two different
EGFR small interfering RNAs (siRNAs) independently knocked
down EGFR expression and inhibited autophagic flux (Figures
1B and 1C), and loss of EGFR markedly reduced endogenous
LC3 puncta formation (Figures 1D and 1E), indicating a role for
EGFR in autophagy initiation.
To determine whether the role for EGFR in autophagy is due to
its overexpression,we tested theeffects of EGFRknockdown in 7
cell lines, four of which do not overexpress EGFR (Figure S1A
available online). Knockdown of EGFR inhibited autophagic flux
in each cell line (Figure S1B), indicating a role in autophagy inde-
pendent of receptor level. Importantly, the role for EGFR in auto-
phagy initiation is receptor selective, as loss of PDGFRB, FGFR2,
or c-Met did not suppress autophagy (Figures S1C–S1E).
Active EGFR blocks autophagy (Wei et al., 2013), and we
confirmed that EGF stimulation inhibits autophagy initiation (Fig-
ure S1F); thus, we hypothesized that inactive EGFR initiates
autophagy. To test this hypothesis, siRNA-resistant wild-type
(WT) or K721A kinase-dead (KD) EGFRwas re-expressed in cells
in which endogenous EGFR was knocked down. Re-expressed(B) Knockdown of EGFR by two distinct siRNAs inhibits LC3-II generation. MDA-M
EGFR siRNA #1 was used in all the remaining experiments.
(C) Quantification of LC3-II levels in (B); mean + SD, n = 3, ***p < 0.001.
(D) CQ induces accumulation of LC3 puncta (autophagosomes) in control cells,
normal medium were pretreated with CQ for 3 hr and fixed for immunostaining o
boxes indicate selected regions for magnified new. Bar, 10 mm.
(E) Quantification of LC3 puncta in (D); mean + SD, n = 3, ***p < 0.001.
(F) Left: re-expression of wild-type (WT) or the K721A kinase-dead (KD) EGFR resc
enhances autophagy rescue by EGFR-WT. siRNA-resistant EGFR-WT or -KDwas
EGFR was knocked down by siRNA #1, and cells were cultured in normal med
analysis. EV, empty vector.
(G) Quantification of LC3-II levels in (F); mean + SD, n = 3, **p < 0.01, ***p < 0.00
(H) Representative images of serum starvation-induced EGFP-LC3 puncta in MD
EGFR-WT or EGFR-KD. EGFP-LC3 was expressed by lentivirus infection and a
Endogenous EGFRwas knocked down by siRNA, and siRNA-resistant WT or KD E
fluorescence microscopy. Bar, 10 mm.
(I) Quantification of the number of EGFP-LC3 puncta in (H); mean + SD, n = 3, **
See also Figure S1.EGFR-WT is autophosphorylated and activates AKT signaling
when stimulated with EGF, but EGFR-KD does not autophos-
phorylate or activate AKT (Figure S1G). However, re-expression
of either WT or KD EGFR rescued autophagic flux in EGFR
knockdown cells (Figures 1F and 1G, left panels), and treatment
of EGFR-WT re-expressing cells with the EGFR TKI gefitinib
enhanced the rescue of autophagy initiation (Figures 1F and
1G, right panels), indicating the role for EGFR in autophagy
initiation is kinase independent. Serum starvation induced an
increase in GFP-LC3 puncta (autophagosomes) (Figure S1H),
and loss of EGFR strongly inhibited autophagosome formation
(Figures 1H and 1I). Re-expression of either WT or KD EGFR fully
rescued the starvation-induced formation of GFP-LC3 puncta in
EGFR knockdown cells (Figures 1H and 1I). These combined
results reveal a kinase-independent role for EGFR in basal and
serum starvation-induced autophagy.
Starvation Induces Accumulation of Inactive EGFR at
LAPTM4B-Positive Endosomes
To explore how inactive EGFR controls autophagy, the subcellu-
lar localization of EGFR in normal and serum-starved cells was
investigated. We previously showed that LAPTM4B inhibits
EGF-stimulated EGFR lysosomal sorting (X.T., Y.S., N.T., Y.
Liao, A.C. Hedman, and R.A.A., unpublished data). Here, we
show that EGFR partially colocalized with LAPTM4B at endo-
somes in cells grown with serum (Figure 2A, top). The specificity
of EGFR immunostaining was confirmed by siRNA knockdown
of EGFR (Figure S2A). Surprisingly, serum-starvation enhanced
EGFR accumulation at LAPTM4B-positive endosomes (Fig-
ure 2A, bottom), which include both late and early endosomes
(Figure S2B). Starvation-induced endosomal EGFR accumula-
tion and EGFR-LAPTM4B colocalization were observed in all
cells assayed (Figures S2C–S2F). Serum starvation also induced
intracellular accumulation of c-Met and FGFR2, and c-Met
colocalized well with LAPTM4B but FGFR2 did not (Figures
S2G–S2J). However, neither FGFR2 nor c-Met was required for
autophagy, indicating that this is an EGFR-selective function
(Figures S1C–S1E).
EGFR translocates to endosomes upon EGF stimulation
and receptor autophosphorylation/activation (Wiley, 2003). WeB-231 cells were cultured in normal medium. Unless otherwise indicated, the
but not in EGFR knockdown cells. Control or EGFR siRNA-transfected cells in
f endogenous LC3 (red) and EGFR (green). DAPI was used to stain the nuclei;
ues LC3-II turnover in EGFR-knockdown cells. Right: gefitinib (2 mM) treatment
expressed inMDA-MB-231 cells by lentivirus-mediated infection. Endogenous
ium and treated with CQ for 2 hr before whole-cell lysate harvest for western
1.
A-MB-231 cells treated with indicated siRNAs with or without re-expression of
monoclonal cell line stably expressing low levels of EGFP-LC3 was selected.
GFR was re-expressed using lentivirus. Cells were serum starved and fixed for
*p < 0.001.
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Figure 2. Serum Starvation Induces Accumulation of Inactive EGFR at LAPTM4B-Positive Endosomes
(A) MDA-MB-231 cells were serum starved or not for 24 hr and fixed for costaining of endogenous EGFR (green) and LAPTM4B (red). Boxes indicate regions for
magnified new.
(B) MDA-MB-231 cells were serum starved (STV) or not, followed by EGF (100 ng/ml) stimulation for 5 or 15 min as indicated. Then cells were fixed for costaining
of EGFR (green) and phosphor-EGFR (Y1068, red).
(C) The whole-cell lysates with or without serum starvation were analyzed by western blot to detect phosphor-EGFR (Y1068) and total EGFR. Different loadings of
the lysates from MDA-MB-231 cells with 5 min EGF (100 ng/ml) stimulation after starvation were used as a standard to quantify phosphor-EGFR levels in cells
without EGF stimulation.
(D) Quantification of the phosphor-EGFR (Y1068) levels in (C); mean + SD, n = 3.
(E) Quantification of endosomal EGFR staining in cells cultured in normal medium, serum-freemedium (STV), or serum-freemedium plus EGF (100 ng/ml, 15min),
as shown in (B); mean + SD, n = 3, **p < 0.01, ***p < 0.001.
(legend continued on next page)
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therefore examined whether the EGFR accumulated at
LAPTM4B-positive endosomes upon serum starvation was
phosphorylated. EGF-stimulatedcellswereusedaspositive con-
trols for phospho-EGFR staining, as shown in Figure 2B. Interest-
ingly, in either serum grown or the starved condition, phospho-
EGFR was not detected by immunofluorescence, but there was
clear endosomal EGFR accumulation (Figure 2B). The endoso-
mal staining of EGFR appears stronger than the plasma mem-
brane staining because of the point concentration at endosomes
(Figures 2A, 2B, and S2). Quantitative western blotting confirmed
that less than 2% of the total EGFR was phosphorylated in cells
cultured in either normal or serum starved medium, assuming
that 5 min stimulation with 100 ng/ml EGF stimulated maximal
EGFR phosphorylation (Figures 2C and 2D). Stimulation of cells
with 100 ng/ml EGF for 15 min causes endocytosis and accumu-
lation of over 95% of total EGFR at endosomes; we therefore
calculated how much of EGFR was accumulated at endosomes
in normal and starved cells by quantifying the endosomal EGFR
staining in these conditions versus the EGF-stimulated (15 min)
condition. This indicated that 20% or 40% of total EGFR is
accumulated at endosomes in normal versus serum-starved
conditions, respectively (Figures 2E and 2F). This demonstrates
that in serum-grown or starved cells the endosomal EGFR is
primarily unphosphorylated. Importantly, upon serum starvation,
the amount of endosomal EGFR increased from 20% to 40%
(Figures 2Band 2F), but the total phospho-EGFR level decreased
(Figures 2C and 2D), indicating that serum starvation-induced
endosomal accumulation of inactive EGFR.
Inactive EGFR and LAPTM4B Interact and Stabilize Each
Other at Endosomes
The interaction between EGFR and LAPTM4B was studied
to explore the mechanism for EGFR endosomal localization.
EGFR was coimmunoprecipitated specifically with LAPTM4B,
but not with other LAPTM members (Figure S3A). Serum starva-
tion increased EGFR endosomal accumulation (Figure 2) and
enhanced the LAPTM4B-EGFR association (Figure 3A), whereas
EGF stimulation reduced the interaction (Figure 3B), indicating
that LAPTM4B preferentially interacts with inactive EGFR. This
was confirmed using the EGFR-KD mutant that has much stron-
ger interaction with LAPTM4B compared with EGFR-WT (Fig-
ure 3C). EGF stimulation did not affect the LAPTM4B interaction
with EGFR-KD (Figure 3D) that is not activated by EGF (Fig-
ure S1G). As serum starvation also induces endosomal accumu-
lation of other receptors, LAPTM4B interaction with PDGFRB,
FGFR2, and c-Met was tested. These receptors also coimmu-
noprecipitated with LAPTM4B (Figure S3B), but none of these
interactions were enhanced upon serum starvation (Figure S3C),
indicating that the serum starvation promoted EGFR-LAPTM4B
interaction is selective.
As LAPTM4B is an endosomal protein (Shao et al., 2003; Ver-
garajauregui et al., 2011), we determined whether LAPTM4B
could modulate EGFR endosomal accumulation. MDA-MB-231(F) Quantification of the relative amount of endosomal EGFR staining in cells cultu
endosomal EGFR staining in cells in serum-free medium plus EGF (100 ng/ml, 1
DAPI was used to stain the nuclei; pEGFR, phosphor-EGFR (Y1068). Bar, 10 mm
See also Figure S2.cells express variable amounts of LAPTM4B, and in cells with
low LAPTM4B, there was less endosomal EGFR (Figure S3D,
arrowhead), suggesting LAPTM4Bmodulation of EGFR localiza-
tion. Strikingly, upon knockdown of LAPTM4B, EGFR endoso-
mal accumulation was lost, but EGFR targeting was fully rescued
by re-expression of siRNA-resistant LAPTM4B (Figure 3E). Loss
of LAPTM4B also resulted in a loss of endosomal EGFR in A431
and HeLa cells, indicating that this was independent of cell type
(Figures S3E and S3F). To confirm that LAPTM4B mediates en-
dosomal accumulation of inactive EGFR, cells stably expressing
C terminally Flag-tagged WT or KD EGFR were generated. Both
WT and KD EGFR had endosomal localization, but this was dis-
rupted by loss of LAPTM4B (Figure 3F), demonstrating that
LAPTM4B is required for the endosomal accumulation of inac-
tive EGFR. Though c-Met and FGFR2 also accumulate at endo-
somes upon serum starvation, LAPTM4B knockdown reduced
the endosomal localization of c-Met, but not of FGFR2 (Figures
S3G and S3H). Interestingly, whereas c-Met localization appears
to be impacted by LAPTM4B, c-Met was not required for auto-
phagy initiation (Figures S1C–S1E).
To further explore LAPTM4B regulation of EGFR endosome
accumulation, a biotinylation assay was used to quantify the
amount of cell-surface EGFR. This demonstrated that although
the total EGFR level was reduced in LAPTM4B knockdown cells,
the level of EGFR at the cell surface was not affected (Figure 3G),
consistent with a specific loss of endosomal EGFR in LAPTM4B
knockdown cells. This indicates that LAPTM4B mediates
endosomal EGFR accumulation by stabilizing inactive EGFR at
endosomes. Likewise, inactive EGFR also stabilizes LAPTM4B
at endosomes, as knockdown of EGFR caused a loss of endo-
somal LAPTM4B staining, and re-expression of either WT or
KD EGFR rescued LAPTM4B staining at endosomes (Figure 3H).
Importantly, the endosomal localization of EGFR or LAPTM4B
is not dependent on Hrs or TSG101 (Figure S3I), both of which
are essential for the ESCRT-mediated EGFR intraluminal sorting
upon ligand stimulation (Sorkin and Goh, 2008). This indicates
that the pathway-mediating accumulation of inactive EGFR at
LAPTM4B-positive endosomes is different from that for ligand
stimulated EGFR endosomal sorting.
LAPTM4B Is Required for Basal and Serum
Starvation-Induced Autophagy
The data suggest that EGFR-dependent autophagy initiation
may be linked to LAPTM4B-mediated EGFR endosomal locali-
zation. To determine if LAPTM4B is required for autophagy,
different siRNAs were used to knockdown LAPTM4B, and
LC3-II turnover was quantified. Both LAPTM4B siRNAs knocked
down LAPTM4B expression and inhibited basal autophagic flux
(Figures 4A–4C). The chloroquine-induced accumulation of
endogenous LC3 puncta was also strongly inhibited in LAPTM4B
siRNA-treated cells (Figures 4D and 4E), phenocopying that
of EGFR knockdown. Similarly, starvation-induced formation
of the GFP-LC3 puncta was markedly decreased upon loss ofred in normal medium or serum-free medium (STV) normalized to the amount of
5 min); mean + SD, n = 3, ***p < 0.001.
.
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LAPTM4B (Figures 4F and 4G). Consistently, ectopic expression
of LAPTM4B increased LC3-II turnover (Figures S4A and S4B),
as well as basal GFP-LC3 puncta formation (Figure S4C), and
re-expression of siRNA-resistant LAPTM4B rescued starva-
tion-induced GFP-LC3 puncta formation in LAPTM4B knock-
down cells (Figure S4D). Significantly, knockdown of EGFR
and LAPTM4B together did not further inhibit LC3-II turnover
compared to the single knockdown of either protein (Figures
S4E and S4F), suggesting that LAPTM4B and EGFR function in
the same pathway.
To explore if EGFR and LAPTM4B have mechanisms inde-
pendent of each other for autophagy initiation, we examined
autophagic turnover in cells with knockdown of one protein
and overexpression of the other. Interestingly, overexpression
of EGFR largely rescued autophagy in LAPTM4B knockdown
cells (Figures S4G and S4H), whereas overexpression of
LAPTM4B weakly, if at all, rescued autophagy in EGFR knock-
down cells (Figures S4I and S4J). This suggests that LAPTM4B
is a cofactor for EGFR-driven autophagy initiation.
Inactive EGFR and LAPTM4B Interact with the Exocyst
for Autophagy Initiation
The data indicate that serum starvation promotes the assembly
of an endosomal EGFR-LAPTM4B complex that regulates auto-
phagy initiation. Recently, exocyst complexes have been impli-
cated in starvation-induced autophagy (Bodemann et al., 2011).
A proteomic screen demonstrated that exocyst subunits interact
with the EGFR complex (Foerster et al., 2013); we therefore
explored if LAPTM4B and inactive EGFR interact with exocyst
complex to modulate autophagy. As shown in Figures 5A and
5B,LAPTM4BandEGFR interactwithmultiplesubunitsof theexo-
cyst complex. Sec8 is a core subunit of the exocyst and in endog-
enous coimmunoprecipitation (coIP), Sec8 associated with
LAPTM4B and EGFR (Figure 5C). Exo70 also interacted with
LAPTM4B and EGFR and localized to subdomains of LAPTM4B-
positive endosomes (Figure 5D), and a fraction of endosomes
were positive for EGFR, LAPTM4B, and Exo70 (Figure 5E).
As LAPTM4B selectively interacts with inactive EGFR, we
determined if exocyst subunits interact similarly. Strikingly,
Sec5 interacted with EGFR-KD much more strongly than with
EGFR-WT (Figures 5F and 5H). Sec6 and Sec8 also associatedFigure 3. Inactive EGFR and LAPTM4B Interact and Stabilize Each Oth
(A) coIP of EGFR-GFP with Flag-LAPTM4B in HEK293 cells cultured in normal o
(B) coIP of EGFR-GFP with Flag-LAPTM4B in HEK293 cells cultured in serum-fre
(C) coIP of wild-type (WT) or kinase-dead (KD) EGFR with Flag-LAPTM4B in HEK
(D) coIP of EGFR-KD with Flag-LAPTM4B in HEK293 cells cultured in serum-free
(E) LAPTM4B is required for the endosomal accumulation of endogenous EGFR.M
the siRNA-resistant LAPTM4B was re-expressed via transient transfection. Cel
(green).
(F) Ectopically expressedwild-type (WT) and kinase-dead (KD) EGFR depend on L
terminally Flag-tagged EGFR-WT or -KD were treated with control or LAPTM4B s
LAPTM4B (red).
(G) Control and LAPTM4B knockdown cells were surface biotinylated, and surface
total EGFR levels (top right), cell-surface EGFR levels (bottom left), and the relat
LAPTM4B knockdown cells; mean + SD, n = 3; ***p < 0.001; ns, not significant.
(H) Inactive EGFR stabilizes endosomal LAPTM4B. MDA-MB-231 cells were trans
with empty vector (EV) or siRNA-resistant EGFR-WT or -KD and starved overnig
WCL, whole-cell lysate; STV, serum starvation. Bar, 10 mm. DAPI was used to st
See also Figure S3.with EGFR-KD more strongly (Figures 5G, 5H, and S5A), but
Exo70 and Exo84 did not (Figures 5H, S5B, and S5C), demon-
strating that inactive EGFR selectively associates with the
Sec5 exocyst subcomplex.
To determine if the Sec5 subcomplex modulates autophagy,
Sec5 was knocked down, and this strongly inhibited basal LC3
turnover (Figures 5I and 5J) and serum starvation-induced
GFP-LC3 puncta formation (Figures 5K and 5L), indicating that
Sec5 is required for basal and serum starvation-induced auto-
phagy initiation. ThiswasunexpectedasSec5has inhibitory roles
in amino acid starvation-induced autophagy (Bodemann et al.,
2011). Sec6, Sec8, and Exo70 also interacted with LAPTM4B
andEGFR (Figures 5A and 5B), and all were required for autopha-
gic turnover in MDA-MB-231 cells (Figures S5D–S5F).
EGFR, LAPTM4B, and Sec5 Regulate Rubicon
Disassociation from the Beclin 1 Complex
Beclin 1 is a core subunit of the autophagy initiation complex
involved in phagophore formation (He and Levine, 2010). To
investigate how inactive EGFR may modulate the Beclin 1 com-
plex, changes in the Beclin 1 interactome (He and Levine, 2010)
upon serum starvation were explored. Although serum starva-
tion-induced strong autophagosome formation and autophagic
flux in cells (Figures 1A and S1H), only the association between
Beclin 1 and the autophagy inhibitor Rubicon was reduced,
whereas the Beclin 1 association with VPS34 or ATG14 was
not affected by serum starvation (Figures 6A and 6E). Impor-
tantly, serum starvation strongly stimulated autophagy in control
cells, but in Rubicon knockdown cells, basal autophagy is
dramatically enhanced, and serum starvation does not further
induce autophagy (Figure S6), signifying that the disassociation
of Rubicon from Beclin 1 is a major mechanism for serum starva-
tion induced autophagy. EGFR, LAPTM4B, and Sec5 appear to
have a collaborative role in autophagy initiation, as loss of any of
these components blocked autophagy (Figures 1, 4, and 5) and
inhibited Rubicon disassociation from Beclin 1 (Figures 6B–6E).
Rubicon strongly and selectively associates with EGFR-KD
(Figure 6F), and consistently, serum starvation significantly
enhanced the coIP of EGFR with overexpressed or endogenous
Rubicon (Figures 6G and 6H), suggesting that inactive EGFR reg-
ulates autophagy by interactingwith Rubicon. To determine if theer at Endosomes
r serum-free medium.
e medium with 0, 2, 10, or 50 ng/ml EGF treatment (30 min).
293 cells in normal medium.
medium with or without 50 ng/ml EGF treatment (30 min).
DA-MB-231 cells were treatedwith control or LAPTM4B siRNA, and after 48 hr,
ls were serum starved and fixed for costaining of LAPTM4B (red) and EGFR
APTM4B for endosomal accumulation. MDA-MB-231 cells stably expressing C
iRNA, serum starved, and fixed for costaining of Flag (green) and endogenous
and total EGFR levels were analyzed bywestern blot (top left). Quantification of
ive amounts of cell-surface EGFR (bottom right) in serum-starved control and
fected with control or EGFR siRNA, and after 48 hr cells, they were transfected
ht, followed by fixing and costaining of EGFR (green) and LAPTM4B (red).
ain the nuclei.
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Figure 4. LAPTM4B Is Required for Basal
and Serum Starvation-Induced Autophagy
(A) Immunofluorescence images showing the
knockdown efficiency of two distinct LAPTM4B
siRNAs. Nuclear staining is nonspecific.
(B) Knockdown of LAPTM4B by two distinct
siRNAs suppresses LC3-II turnover in MDA-
MB-231 cells cultured in normal medium. CQ,
chloroquine.
(C) Quantification of LC3-II in (B); mean + SD, n = 3,
***p < 0.001.
(D) Knockdown of LAPTM4B results in a loss
of chloroquine (CQ)-induced accumulation of
endogenous LC3 puncta. Note: different from
Figure 3E, some EGFR intracellular puncta were
observed here in LAPTM4B knockdown cells
because of chloroquine treatment that blocked
basal EGFR lysosomal degradation. Boxes are
selected regions for magnified view.
(E) Quantification of the number of LC3 puncta in
(D); mean + SD, n = 3, ***p < 0.001.
(F) Knockdown of LAPTM4B causes a loss of
serum starvation-induced EGFP-LC3 puncta for-
mation. MDA-MB-231 cells stably expressing low
levels of EGFP-LC3 as described in Figure 1H
were treated with control or LAPTM4B siRNA and
serum starved or not before fixing for microscopy.
(G) Quantification of the number of EGFP-LC3
puncta in (F); mean + SD, n = 3; ns, not significant;
***p < 0.001.
Bar, 10 mm. DAPI was used to stain the nuclei.
See also Figure S4.EGFR C-tail (EGFR-CT) could modulate the Rubicon-Beclin 1
interaction in vitro, the Beclin 1 complex was purified by immu-
noprecipitation (IP) and incubated with purified glutathione
S-transferase (GST) or EGFR-CT. As shown in Figures 6I and
6J, incubation with EGFR-CT efficiently disassociated Rubicon
from Beclin 1 in vitro. The EGFR-CT lacks the kinase domain
and is not phosphorylated, consistent with the concept that
the inactive EGFR functions as a nonphosphorylated receptor
in autophagy initiation and removes Rubicon from the Beclin 1
complex.
LAPTM4B is overexpressed in most epithelial cancers, and
increased LAPTM4B expression enhanced the EGFR interaction
with Rubicon and Sec5 (Figure 6K). Sec5 has been shown to
associate with Rubicon (Bodemann et al., 2011), and the knock-
down of either LAPTM4B or Sec5 diminished the Rubicon inter-
action with EGFR (Figures 6L and 6M), indicating that LAPTM4B
and Sec5 facilitate the Rubicon interaction with inactive EGFR.
Thus, the endosomal inactive EGFR, with LAPTM4B and Sec5,152 Cell 160, 145–160, January 15, 2015 ª2015 Elsevier Inc.promotes disassociation of Rubicon
from the Beclin 1 complex, which in turn
initiates autophagy.
Erlotinib and Gefitinib Induce a
Sec5-Dependent Role for Inactive
EGFR in Autophagy Initiation
The EGFR TKIs erlotinib and gefitinib
induce autophagy in multiple cancer celllines, and the underlying mechanisms have been linked to the in-
hibition of the downstream PI3K/AKT/mTOR pathway and/or the
inhibition of EGFR-mediated Beclin 1 phosphorylation (Dragow-
ska et al., 2013; Jutten and Rouschop, 2014; Sobhakumari et al.,
2013; Wei et al., 2013). The role for inactive EGFR in autophagy
initiation suggests that EGFR TKIs may induce a direct role
for EGFR in autophagy. At clinically relevant concentrations
(Baselga et al., 2002; Soulieres et al., 2004), erlotinib or gefitinib
stimulated autophagic activity comparable to that induced by
serum starvation or rapamycin (Figures 7A, S7A, and S7B).
Further, TKI-induced autophagy is EGFR dependent as loss of
EGFR strongly suppressed gefitinib-induced autophagy (Figures
7B and 7C). TKIs downregulated phosphorylation of EGFR, but
not of Akt (Figure 7D), consistent with a direct role for inactive
EGFR, but not for Akt/mTOR inactivation, in the EGFR TKI-
induced autophagy.
As erlotinib and gefitinib inhibit EGFR kinase activity, we inves-
tigated whether the EGFR-LAPTM4B-Sec5 pathway is required
(legend on next page)
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for autophagy initiation. Erlotinib and gefitinib inhibited the inter-
action between EGFR and LAPTM4B (Figures 7E and 7I) but
still stimulated accumulation of EGFR at endosomes (Figures
7F and S7C), similar to serum starvation (Figure 2). The EGFR
interactions with Sec5, Sec6, and Rubicon were all enhanced
by erlotinib or gefitinib (Figures 7G–7I and S7D). As with serum
starvation, erlotinib or gefitinib also promoted Rubicon disasso-
ciation from the Beclin 1 complex (Figure 7J), indicating that
erlotinib and gefitinib induce a LAPTM4B-independent role for
EGFR in Rubicon regulation. Finally and consistently, whereas
Sec5 and LAPTM4B were required for basal autophagy (Figures
7K and 7L, left), loss of Sec5, but not of LAPTM4B, inhibited the
gefitinib- (or erlotinib-; not shown) stimulated LC3-II turnover
(Figures 7K and 7L, right). Together, these results reveal that
the EGFR TKIs, erlotinib and gefitinib, stimulate a direct role for
inactive EGFR in autophagy initiation that is dependent on
Sec5 but is independent of LAPTM4B.
Together, the data suggest a model that serum starvation
induces LAPTM4B-dependent EGFR accumulation at endo-
somes, where inactive EGFR synergizes with LAPTM4B and
Sec5 in stimulating autophagy initiation independently of its tyro-
sine kinase activity by facilitating the disassociation of Rubicon
from Beclin 1 (Figure 7M, top). Similarly, EGFR TKIs induce
LAPTM4B-independent accumulation of EGFR at endosomes,
where EGFR associates with Sec5 andRubicon to release Beclin
1 for autophagy initiation (Figure 7M, bottom).
DISCUSSION
Autophagy is activated inmany cancers and facilitates cancer cell
survival in stressed conditions (Brech et al., 2009; White, 2012).
EGFR plays crucial roles in many epithelial cancers, and its
signaling has been linked to prosurvival, proliferative, and prome-
tastatic functionsof cancercells (MendelsohnandBaselga,2006).
There are multiple links of EGFR to autophagy: (1) EGFR signaling
activates the PI3K/AKT/mTOR pathway that inhibits autophagy;
(2) activated EGFR directly phosphorylates and inhibits Beclin 1,
a key component in autophagy initiation; and (3) EGFR TKIs upre-
gulate autophagy in many cancer cells (Jutten and Rouschop,
2014; Li and Fan, 2010;Wei et al., 2013). These studies all support
a role for EGFR signaling in autophagy suppression.
Our data reveal a direct and unexpected role for inactive EGFR
in autophagy initiation. Upon serum starvation, inactive EGFRFigure 5. Inactive EGFR and LAPTM4B Interact with Exocyst for Autop
(A and B) coIP of LAPTM4B or EGFR with different exocyst subunits in HEK293
(C) Endogenous coIP of Sec8 with LAPTM4B or EGFR in MDA-MB-231 cells.
(D) Colocalization of LAPTM4B and Exo70-Flag. MDA-MB-231 cells were fixed and
the nuclei.
(E) Colocalization of LAPTM4B (red), EGFR-GFP (green), and Exo70-Flag (blue) i
(F and G) coIP of EGFR-WT or -KD with Sec5 or Sec6 in HEK293 cells cotransfe
(H) Quantification of the relative amounts of different exocyst subunits coimmun
*p < 0.05; ***p < 0.001.
(I) Knockdown of Sec5 suppresses LC3-II turnover in MDA-MB-231 cells culture
(J) Quantification of LC3-II levels in (I); mean + SD, n = 3; ***p < 0.001.
(K) Knockdown of Sec5 suppresses serum starvation-induced EGFP-LC3 punct
(L) Quantification of the number of EGFP-LC3 puncta in (K); mean + SD, n = 3; **
Boxes are selected regions for magnified new. Bar, 10 mm.
See also Figure S5.
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the Sec5 exocyst subcomplex. This EGFR complex binds the
autophagy inhibitor Rubicon, resulting in its disassociation
from Beclin 1, releasing the Rubicon-free Beclin 1 complex to
initiate autophagy (Figure 7M, top). These results establish the
concept that whereas in nutrient-rich conditions activated
EGFR suppresses autophagy and promotes cancer cell prolifer-
ation and survival through agonist stimulated EGFR signaling, in
metabolically stressed conditions inactive EGFR alternatively fa-
cilitates cancer cell survival by activating autophagy. Consistent
with our findings, kinase-independent roles for EGFR in cancer
cell survival have been reported (Coker et al., 1994; Ewald
et al., 2003; Weihua et al., 2008), and cancer cells expressing
EGFR have been shown to depend on autophagy for survival
and growth (Jutten et al., 2013; Jutten and Rouschop, 2014;
Sakuma et al., 2013).
In clinical treatments, the EGFR TKIs erlotinib and gefitinib are
effective in non-small-cell lung cancers (NSCLCs) that have
activating mutations in EGFR, but show no effects in most solid
tumors with WT EGFR (Mendelsohn and Baselga, 2006; Paez
et al., 2004). Recent studies have shown that treatment with
EGFR TKIs increased autophagy with cytoprotective effects in
many cancer cells (Dragowska et al., 2013; Eimer et al., 2011;
Gorzalczany et al., 2011; Han et al., 2011; Jutten and Rouschop,
2014; Li et al., 2013; Sakuma et al., 2013; Sobhakumari et al.,
2013; Zou et al., 2013). EGFR TKIs activate autophagy by block-
ing the role for active EGFR in autophagy suppression in lung
cancer cells with activating EGFR mutations (Wei et al., 2013),
but the mechanism by which the EGFR TKIs induce autophagy
in cancer cells with WT EGFR was not defined. We show that
EGFR TKIs induce a direct role for inactivated EGFR in auto-
phagy initiation. EGFR TKIs mimic serum starvation and trigger
endosomal accumulation of inactive EGFR that gains enhanced
interaction with the Sec5 exocyst subcomplex and Rubicon,
releasing Beclin 1 to initiate autophagy (Figure 7M, bottom).
Thus, though EGFR TKIs block the cellular functions mediated
by EGFR kinase signaling, they activate a role for inactive
EGFR in autophagy that could potentially provide a survival
advantage and TKI resistance in WT EGFR-expressing cancers.
In fact, there is in vitro and in vivo evidence that cotargeting
EGFR and autophagy is a promising strategy to overcome TKI
resistance of cancer cells with WT EGFR, even when these can-
cer cells carry a different oncogenic factor like K-Ras or p53hagy Initiation
cells cotransfected with indicated proteins.
stained with anti-LAPTM4B (red) and anti-Flag (green). DAPI was used to stain
n MDA-MB-231 cells.
cted with indicated proteins.
oprecipitated with EGFR-WT or -KD; mean + SD, n R 3; ns, not significant;
d in normal medium.
a formation in MDA-MB-231 cells.
*p < 0.001.
Figure 6. EGFR, LAPTM4B, and Sec5 Regulate Rubicon Disassociation from the Beclin 1 Complex
(A) coIP of Beclin 1 with ATG14, VPS34, and Rubicon in normal (N) and serum-starved (S) MDA-MB-231 cells.
(B–D) coIP of Beclin 1 with VPS34 and Rubicon in serum-starved MDA-MB-231 cells pretreated with indicated siRNAs.
(E) Quantification of relative Rubicon association with Beclin 1 in (A-D); mean + SD, n = 3; **p < 0.01; ***p < 0.001.
(F) coIP of Rubicon with EGFR-WT or -KD in HEK293 cells cotransfected with indicated proteins.
(G) coIP of EGFR with Flag-Rubicon or endogenous Rubicon in normal (N) and serum-starved (S) conditions. Asterisk indicates a nonspecific band.
(H) Quantification of relative Rubicon association with EGFR in (G); mean + SD, n = 3; **p < 0.01.
(I) Endogenous Beclin 1 complex was immunoprecipitated from MDA-MB-231 cells using anti-Beclin 1. The beads with immunocomplex were washed, divided
into equal volumes, and then incubated with purified GST or EGFR-C tail (EGFR-CT; amino acids 959–1186) for 20min at room temperature. Changes of Rubicon
association with Beclin 1 after the incubation were analyzed by western blot.
(legend continued on next page)
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mutation (Choi et al., 2013; Dragowska et al., 2013; Jutten and
Rouschop, 2014; Zou et al., 2013). For example, while erlotinib
or hydroxychloroquine (HCQ; a clinically available autophagy in-
hibitor) alone show no antitumor activity in xenografts derived
from H460 NSCLC cells expressing WT EGFR but mutant K-
Ras, combination of the two drugs resulted in dramatic inhibition
of tumor growth (Zou et al., 2013). A recent clinical trial has
confirmed the safety and tolerance for cotreatment of erlotinib
with HCQ (Goldberg et al., 2012), and additional trials combining
HCQ with erlotinib or gefitinib are ongoing for the treatment of
NSCLC.
EGFR and/or LAPTM4B are overexpressed in the majority of
human cancers and contribute to cancer cell survival and prolif-
eration (Kasper et al., 2005; Shao et al., 2003). The results
presented here highlight the roles for the oncoprotein LAPTM4B
in EGFR-mediated cell survival functions. We have previously
shown that LAPTM4B promotes active EGFR signaling by
blocking EGF-stimulated EGFR intraluminal sorting and lyso-
somal degradation (X.T., Y.S., N.T., Y. Liao, A.C. Hedman, and
R.A.A., unpublished data). In the EGF-stimulated condition,
LAPTM4B has a weak interaction with EGFR, but it inhibits the
function of Hrs, a key subunit of the endosomal sorting complex
required for transport-0 (ESCRT-0), through enhancing the ubiq-
uitination of Hrs by the E3 ubiquitin ligase Nedd4 (X.T., Y.S., N.T.,
Y. Liao, A.C. Hedman, and R.A.A., unpublished data). Here,
we show that upon serum starvation, LAPTM4B senses EGFR
inactivation at endosomes and selectively forms a complex
with inactive EGFR to initiate autophagy. In both conditions,
LAPTM4B facilitates the prosurvival functions of EGFR in cancer
cells. The lack of a requirement for LAPTM4B in EGFR-TKIs-
induced autophagy is not surprising, as LAPTM4B appears to
be a cofactor for EGFR-driven autophagy, and the effects of
LAPTM4B knockdown on autophagy can be largely compen-
sated by EGFR overexpression (Figures S4G and S4H). Impor-
tantly, in chemotherapies, LAPTM4B appears to increase drug
resistance by multiple mechanisms (Li et al., 2010a, 2010c).
Thus, although LAPTM4B is not required for the erlotinib/
gefitinib-induced EGFR functions in autophagy initiation, it may
enhance EGFR-TKI resistance through other pathways. This
supports LAPTM4B as a therapeutic target for EGFR-positive
cancers or a combined target for anti-EGFR therapies.
Multivesicular endosomes (MVEs) and autophagosomes are
closely related as in mammalian cells autophagosomes often
fuse with endosomes to form amphisomes before the final
formation of autolysosomes (Fader and Colombo, 2009; Lamb
et al., 2013). Therefore, endosomes have an established role
in autophagosome maturation. Our results demonstrate that
the endosome-localized inactive EGFR and LAPTM4B play
pivotal roles in autophagy initiation. This emphasizes the impor-
tance of endosomes not only as canonical degradative com-
partments of the autophagosome content but also as signaling(J) Quantification of relative Rubicon association with Beclin 1 in (I); mean + SD,
(K) LAPTM4B overexpression facilitates EGFR coIP with Rubicon and Sec5 in HE
(L) Knockdown of LAPTM4B or Sec5 diminishes Rubicon coIP with EGFR in seru
(M) Quantification of relative Rubicon association with EGFR in (L); mean + SD, n
N, normal medium with serum; S, STV, serum-free starvation medium; WCL, wh
See also Figure S6.
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mediated Rubicon-Beclin 1 disassociation may occur at the
endosomal surface, but the Beclin 1 complex functions in
autophagosomal membrane nucleation at the endoplasmic
reticulum (ER) (Hamasaki et al., 2013; Lamb et al., 2013). This
suggests that the phagophore initiation sites at ER are in close
proximity to endosomal Beclin 1-releasing sites. In support of
this, LC3 puncta were observed adjacent to EGFR-positive
endosomes (Figures 1D and 4D, top panels), suggesting that
autophagosomes are formed at the ER close to EGFR-positive
endosomes. Consistently, there are tight associations between
the ER network and endosomes through ER-endosome con-
tacts in mammalian cells (Eden et al., 2010; Friedman et al.,
2013; Helle et al., 2013). Although most studies have focused
on the roles for ER, mitochondria and Golgi in phagophore
initiation, the ER-endosome contact sites are positioned to
play key roles. In this case, autophagosome maturation could
be coupled, as autophagosomes would be formed close to
endosomes.
In summary, this study identifies a key role for inactive EGFR in
autophagy initiation in cells with WT EGFR gene in both serum
starved and EGFR TKIs-treated cells. It provides insights into
the mechanistic regulation of cancer cell survival by EGFR
expression in metabolically stressed tumors and suggests a ba-
sis for EGFR TKI resistance in the treatments of tumors without
EGFR mutations.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, Plasmids, siRNA, Antibodies, and
Reagents
MDA-MB-231, HeLa, A431, and HEK293 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Corning) with 10% fetal bovine serum
(FBS) (Invitrogen). Transfection of plasmids and siRNA oligonucleotides was
carried out using Lipofectamine 2000 and Lipofectamine RNAiMax (Invitro-
gen), respectively, following themanufacturer’s instructions. For serum starva-
tion, cells were washed with DMEM twice and cultured in DMEM without FBS
for the indicated time periods. A detailed description of reagents, DNA
plasmids, antibody origins, siRNA sequences, and cell treatments is included
in the Extended Experimental Procedures.
Immunofluorescence Microscopy
Immunostaining of tagged and endogenous proteins was performed using
standard procedures. Cells on glass coverslips were washed, fixed, permea-
bilized, blocked, and stained with indicated antibodies. Cells were mounted
using Vectashield and visualized with a Nikon TE2000-U microscope.
Colocalization quantification was performed using the Coloc 2 plugin for Fiji
(ImageJ). See the Extended Experimental Procedures for details.
CoIP and Western Blotting Assays
Immunoprecipitation of indicated proteins was performed using nondenatur-
ing cell extracts. Immunocomplex and whole-cell lysates were analyzed by
SDS-PAGE, followed by immunoblotting with indicated antibodies. See the
Extended Experimental Procedures for details.n = 5; ***p < 0.001.
K293 cells.
m-starved MDA-MB-231 cells.
= 3; **p < 0.01; ***p < 0.001.
ole-cell lysate.
Figure 7. Erlotinib and Gefitinib Induce a Sec5-Dependent Role for Inactive EGFR in Autophagy Initiation
(A) The EGFR TKIs, erlotinib and gefitinib, induce autophagy inMDA-MB-231 cells. Cells were treatedwith DMSOor 2 mMof erlotinib or gefitinib for 24 hr, followed
by 2 hr of 80 mM chloroquine (CQ) treatment as indicated, and whole-cell lysates were analyzed for LC3 levels.
(legend continued on next page)
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Autophagy Assays
Autophagy was analyzed by (1) Western blotting detection of LC3-II turnover in
the presence and absence of autophagy inhibitor chloroquine, (2) quantifying
chloroquine-induced accumulation of endogenous LC3 puncta, and (3) quan-
tifying of the number of EGFP-LC3 puncta in cells stably expressing low levels
of EGFP-LC3 using fluorescence microscopy. See the Extended Experimental
Procedures for details.
Biotinylation Assay
Cells were surface biotinylated and harvested for purification of biotinylated
proteins using streptavidin affinity gel. Whole-cell lysates and purified bio-
tinylated proteins were analyzed by immunoblotting. See the Extended Exper-
imental Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.12.006.
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